SR 142948A, >=98% (HPLC)

SR 142948A, >=98% (HPLC)

Application

SR 142948A was used to study the role of neurotensin signaling in intracellular alkanization and expression of IL-8 in human pancreatic cancer cells.

Biochem/physiol Actions

SR 142948A is a non-peptide Neurotensin receptor antagonist

SR 142948A is a potent neurotensin receptor antagonist that affects the expression of c-Fos and has properties of antipsychotic agent. It blocks hypothermia and analgesia induced by neurotensin. It blocks the increase in the concentration of Ca+2 induced by the activation of phospholipase C in CHO cell model.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is featured on the Neurotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573978 SR 142948A, >=98% (HPLC) white to beige 100 CUYNEHGBVHUQQW-BVJGGMLGSA-N 1S/C39H51N5O6.ClH/c1-23(2)29-21-26(37(46)43(5)15-9-14-42(3)4)12-13-31(29)44-32(35-33(49-6)10-8-11-34(35)50-7)22-30(41-44)36(45)40-39(38(47)48)27-17-24-16-25(19 SIGMA-ALDRICH powder ≥98% (HPLC)
£870.54 (exc VAT) per 25MG
-
+
3573979 SR 142948A, >=98% (HPLC) white to beige 100 CUYNEHGBVHUQQW-BVJGGMLGSA-N 1S/C39H51N5O6.ClH/c1-23(2)29-21-26(37(46)43(5)15-9-14-42(3)4)12-13-31(29)44-32(35-33(49-6)10-8-11-34(35)50-7)22-30(41-44)36(45)40-39(38(47)48)27-17-24-16-25(19 SIGMA-ALDRICH powder ≥98% (HPLC)
£220.07 (exc VAT) per 5MG
-
+